We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+23.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$147M
AUM Growth
-$44.4M
Cap. Flow
-$65.4M
Cap. Flow %
-44.37%
Top 10 Hldgs %
60.34%
Holding
94
New
22
Increased
8
Reduced
10
Closed
28

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$9.68M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$5.26M
3
SVRA icon
Savara
SVRA
+$5.11M
4
VERA icon
Vera Therapeutics
VERA
+$3.57M
5
INSM icon
Insmed
INSM
+$3.11M

Top Sells

Rank Stock Value
1
CBAY
Cymabay Therapeutics
CBAY
+$12.3M
2
IMGN
Immunogen Inc
IMGN
+$11.5M
3
GPCR icon
Structure Therapeutics
GPCR
+$7.82M
4
BHVN icon
Biohaven
BHVN
+$7.46M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$6.36M

Sector Composition

Rank Sector Weight
1 Healthcare 88.88%
2 Communication Services 0.3%
3 Industrials 0.07%
4 Consumer Staples 0.05%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRI
76
GRI Bio
GRI
$2.6M
– –
-12
Closed -$808K
HRMY icon
77
Harmony Biosciences
HRMY
$2.24B
– –
-117,000
Closed -$3.83M
IMVT icon
78
PUT
Immunovant
IMVT
$8.25B
– –
-300,000
Closed -$11.5M
JSPR icon
79
Jasper Therapeutics
JSPR
$23.6M
– –
-286,800
Closed -$2.01M
FNUC
80
Frontier Nuclear and Minerals Inc
FNUC
$44.7M
– –
-16,876
Closed -$290K
MLTX icon
81
MoonLake Immunotherapeutics
MLTX
$1.55B
– –
-88,000
Closed -$5.02M
MRSN
82
DELISTED
Mersana Therapeutics
MRSN
– –
-42,365
Closed -$1.35M
PHAT icon
83
Phathom Pharmaceuticals
PHAT
$692M
– –
-220,000
Closed -$2.28M
PRAX icon
84
Praxis Precision Medicines
PRAX
$10.1B
– –
-43,333
Closed -$1.11M
REPL icon
85
Replimune Group
REPL
$1.01B
– –
-155,000
Closed -$2.65M
SPRY icon
86
PUT
ARS Pharmaceuticals
SPRY
$612M
– –
-100,000
Closed -$378K
SRPT icon
87
Sarepta Therapeutics
SRPT
$1.77B
– –
-29,300
Closed -$3.55M
KRTX
88
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-34,000
Closed -$5.75M
IMGN
89
DELISTED
Immunogen Inc
IMGN
– –
-725,000
Closed -$11.5M
OHAAW
90
DELISTED
OPY Acquisition Corp. I Warrant
OHAAW
– –
-50,000
Closed -$1.39K
HCDIW
91
DELISTED
Harbor Custom Development, Inc. Warrant
HCDIW
– –
-600,000
Closed -$4.5K
HCDIZ
92
DELISTED
Harbor Custom Development, Inc. Warrant
HCDIZ
– –
-650,000
Closed -$6.43K
DRCTW
93
DELISTED
Direct Digital Holdings, Inc. Warrant
DRCTW
– –
-180,000
Closed -$108K
RACYW
94
DELISTED
Relativity Acquisition Corp. Warrant
RACYW
$0 ﹤0.01%
100,000
– –
1 2 3
4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Altium Capital Management held 94 positions worth $147M, down 23% from $192M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Altium Capital Management withdrew a net $65.4M in Q4 2023, closing 28 positions and reducing 10 holdings. Its most notable exit was Immunogen Inc, an estimated $11.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Communication Services and Industrials.

Against the trend, Altium Capital Management opened a new position in Alpha Architect 1-3 Month Box ETF worth $9.75M.

  • Altium Capital Management's largest Q4 2023 buy was Alpha Architect 1-3 Month Box ETF: 92,700 shares worth $9.75M.
  • Altium Capital Management added most to Vera Therapeutics in Q4 2023, an estimated $3.57M increase.
  • Altium Capital Management's biggest Q4 2023 reduction was Cymabay Therapeutics, cutting an estimated $12.3M.
  • Altium Capital Management fully exited Immunogen Inc in Q4 2023, selling an estimated $11.5M.
  • Altium Capital Management's ten largest holdings make up 60% of its $147M portfolio in Q4 2023.
  • Altium Capital Management opened 22 new positions and closed 28 in Q4 2023.
  • Altium Capital Management's portfolio value fell 23% quarter-over-quarter to $147M.

Based on Altium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.